Immutep Limited (IMMP): Price and Financial Metrics

Immutep Limited (IMMP): $2.93

0.13 (+4.64%)

POWR Rating

Component Grades













Add IMMP to Watchlist
Sign Up

Industry: Biotech



in industry


  • Quality is the dimension where IMMP ranks best; there it ranks ahead of 53.22% of US stocks.
  • IMMP's strongest trending metric is Stability; it's been moving up over the last 179 days.
  • IMMP ranks lowest in Momentum; there it ranks in the 4th percentile.

IMMP Stock Summary

  • IMMP's price/sales ratio is 74.19; that's higher than the P/S ratio of 97.06% of US stocks.
  • With a year-over-year growth in debt of -66.67%, IMMUTEP Ltd's debt growth rate surpasses only 4.46% of about US stocks.
  • Revenue growth over the past 12 months for IMMUTEP Ltd comes in at -72.57%, a number that bests only 1.75% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to IMMUTEP Ltd are VALN, GLPG, HIMX, GOVX, and ERYP.
  • IMMP's SEC filings can be seen here. And to visit IMMUTEP Ltd's official web site, go to

IMMP Stock Price Chart Interactive Chart >

Price chart for IMMP

IMMP Price/Volume Stats

Current price $2.93 52-week high $5.44
Prev. close $2.80 52-week low $2.02
Day low $2.71 Volume 446,400
Day high $3.02 Avg. volume 149,111
50-day MA $2.62 Dividend yield N/A
200-day MA $3.25 Market Cap 253.81M

Immutep Limited (IMMP) Company Bio

Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ‘eftilagimod alpha' or ‘efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

IMMP Latest News Stream

Event/Time News Detail
Loading, please wait...

IMMP Latest Social Stream

Loading social stream, please wait...

View Full IMMP Social Stream

Latest IMMP News From Around the Web

Below are the latest news stories about IMMUTEP Ltd that investors may wish to consider to help them evaluate IMMP as an investment opportunity.

Is Immutep (ASX:IMM) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Yahoo | February 24, 2022

Immutep to Present at Healthcare Investor Conferences

SYDNEY, AUSTRALIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announces Immutep has been invited present at investor conferences, as outlined below. 42nd Annual Cowen Health Care Conference - 7 to 9 March 2022 Presenter: Marc Voigt, CEO of ImmutepPresentation time & date: 9:10 am – 9:40 am Eastern Standard Time (EST) on

Yahoo | February 24, 2022

Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022

SYDNEY, AUSTRALIA, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new data is scheduled to be presented at ESMO’s European Lung Cancer Congress (ELCC) 2022 which will take place in-person in Prague, Czech Republic and virtually from 30 March to 2 April 2022, Central European Summer Time (CEST). The new data relates to Immutep’s phase II TACTI-002 trial evaluating its lead product candidate, eftilagimod alpha (“efti”

Yahoo | February 18, 2022

Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor

SYDNEY, AUSTRALIA, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 2016205983) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the Australian Patent Office. This new Australian patent follows the grant of the corresponding European, United St

Yahoo | February 11, 2022

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Immutep (IMMP) and Sanofi (OtherSNYNF)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report), Immutep (IMMP – Research Report) and Sanofi (SNYNF – Research Report). Roche Holding AG (RHHVF) In a report released yesterday, Michael Leuchten from UBS maintained a Hold rating on Roche Holding AG, with a price target of CHF360.00. The company's shares closed last Thursday at $381.00.

Howard Kim on TipRanks | February 4, 2022

Read More 'IMMP' Stories Here

IMMP Price Returns

1-mo 22.08%
3-mo 25.75%
6-mo -10.67%
1-year -41.87%
3-year 47.98%
5-year 19.11%
YTD -10.67%
2021 4.46%
2020 75.42%
2019 -2.72%
2018 17.20%
2017 -32.91%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7847 seconds.